Genovese_Kremer_Mar2017
Response rate (%) Response rate (%) Results – ACR20, ACR50 and ACR70 response rates at Week 12 90 80 70 60 50 40 30 20 * *** ** Study 1 (MTX-IR) 1 Study 2 (TNF-IR) 2 Placebo * *** ** * * ** ** * * 90 80 70 60 50 40 30 20 * ** *** *** * ** ** ** ** ** ABT-494 3 mg BID ABT-494 6 mg BID ABT-494 12 mg BID ABT-494 18 mg BID ABT-494 24 mg QD 10 10 0 ACR20 ACR50 ACR70 0 ACR20 ACR50 ACR70 *P
Response rate (%) Response rate (%) Results – DAS28(CRP) Change From Baseline at Week 12 60 60 Study 1 (MTX-IR) 1 Study 2 (TNF-IR) 2 DAS28(CRP)3.2 50 ** *** ** ** 50 ** DAS(CRP)
- Page 1 and 2: Phase 2b Studies of ABT-494, a Sele
- Page 3 and 4: Background and Objectives • ABT-4
- Page 5 and 6: Methods - Study Design • These we
- Page 7 and 8: Results - Baseline Demographics and
- Page 9: Results - Primary Endpoint MTX inad
- Page 13 and 14: Results - Safety Data Through Week
- Page 15: Conclusions • Selective JAK-1 inh
Response rate (%)<br />
Response rate (%)<br />
Results – ACR20, ACR50 and ACR70 response rates at Week 12<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
*<br />
***<br />
**<br />
Study 1 (MTX-IR) 1 Study 2 (TNF-IR) 2 Placebo<br />
*<br />
***<br />
**<br />
* *<br />
**<br />
**<br />
* *<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
*<br />
**<br />
***<br />
***<br />
*<br />
**<br />
**<br />
**<br />
** **<br />
ABT-494 3 mg BID<br />
ABT-494 6 mg BID<br />
ABT-494 12 mg BID<br />
ABT-494 18 mg BID<br />
ABT-494 24 mg QD<br />
10<br />
10<br />
0<br />
ACR20 ACR50 ACR70<br />
0<br />
ACR20 ACR50 ACR70<br />
*P
Change language